tetano
Editor, Senior Moderator
Open Forum Infect Dis
. 2021 Jun 10;8(7)
fab305.
doi: 10.1093/ofid/ofab305. eCollection 2021 Jul.
The Efficacy of Bamlanivimab in Reducing Emergency Department Visits and Hospitalizations in a Real-world Setting
Douglas S Corwin[SUP] 1 [/SUP], Peter T Ender[SUP] 2 [/SUP], Nitasa Sahu[SUP] 1 [/SUP], Ryan A Durgham[SUP] 3 [/SUP], Dennis M McGorry Jr[SUP] 4 [/SUP], Awan Rahman[SUP] 1 [/SUP], Jill Stoltzfus[SUP] 5 [/SUP], Jeffrey A Jahre[SUP] 2 [/SUP]
Affiliations
Abstract
Bamlanivimab, a monoclonal antibody targeting the spike protein of severe acute respiratory syndrome coronavirus 2, is available for ambulatory treatment of coronavirus disease 2019 (COVID-19). This real-world study confirms the efficacy of bamlanivimab in reducing hospital admissions and emergency department visits among high-risk outpatients with mild to moderate COVID-19 illness and reveals a trend toward improved mortality.
Keywords: COVID-19; bamlanivimab; outcomes; treatment.
. 2021 Jun 10;8(7)
fab305.doi: 10.1093/ofid/ofab305. eCollection 2021 Jul.
The Efficacy of Bamlanivimab in Reducing Emergency Department Visits and Hospitalizations in a Real-world Setting
Douglas S Corwin[SUP] 1 [/SUP], Peter T Ender[SUP] 2 [/SUP], Nitasa Sahu[SUP] 1 [/SUP], Ryan A Durgham[SUP] 3 [/SUP], Dennis M McGorry Jr[SUP] 4 [/SUP], Awan Rahman[SUP] 1 [/SUP], Jill Stoltzfus[SUP] 5 [/SUP], Jeffrey A Jahre[SUP] 2 [/SUP]
Affiliations
- PMID: 34258324
- PMCID: PMC8272954
- DOI: 10.1093/ofid/ofab305
Abstract
Bamlanivimab, a monoclonal antibody targeting the spike protein of severe acute respiratory syndrome coronavirus 2, is available for ambulatory treatment of coronavirus disease 2019 (COVID-19). This real-world study confirms the efficacy of bamlanivimab in reducing hospital admissions and emergency department visits among high-risk outpatients with mild to moderate COVID-19 illness and reveals a trend toward improved mortality.
Keywords: COVID-19; bamlanivimab; outcomes; treatment.